Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2025-06-25 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Insight Event for Retail Investors
Regulatory Filings Classification · 1% confidence The document is an announcement from N4 Pharma plc regarding an upcoming 'Investor Insight Event' for retail investors. It provides details about the event date, location, and the topics to be covered by the management team. It does not contain the actual presentation materials or financial results, but rather serves as a notification of an event. Under the provided definitions and the 'Menu vs Meal' rule, this is a regulatory announcement (RNS) regarding a corporate event, which fits best under the 'Regulatory Filings' category as it is a press release distribution via RNS.
2025-06-25 English
Final Results, Annual Report and Notice of AGM
Report Publication Announcement Classification · 1% confidence The document is an RNS announcement from N4 Pharma PLC. While it contains a 'Chairman's Statement' and financial summaries, the document's primary purpose is to announce the 'Final Results' and the 'Posting of Annual Report and Notice of AGM'. According to the 'MENU VS MEAL' rule, since this is an announcement of the publication of the Annual Report rather than the full Annual Report itself, it is classified as a Report Publication Announcement (RPA). FY 2024
2025-06-06 English
Establishment of New Senior Leadership Team
Board/Management Information Classification · 1% confidence The document is an official announcement released via RNS (Regulatory News Service), indicated by the 'RNS Number : 0805K' and the concluding statement referencing 'Reach, the non-regulatory press release distribution service of RNS'. The content explicitly announces the 'Establishment of New Senior Leadership Team' and details the new members and their roles (Head of R&D, Head of Strategy, Commercial Director, Head of CMC). This directly relates to changes in senior management personnel. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is substantial enough (7861 chars) that it is the primary announcement, not just a brief notice of publication (RPA).
2025-05-27 English
TR-1: Notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains structured data fields typical of regulatory filings concerning changes in significant share ownership. Key indicators include 'RNS Number', 'N4 Pharma PLC', 'TR-1: Standard form for notification of major holdings', and the tracking of voting rights percentages crossing a threshold (from 9.12% to 8.89%). This directly corresponds to the definition of a Major Shareholding Notification.
2025-05-23 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains fields related to voting rights, share ownership thresholds, and notification dates (21 May 2025). This structure is characteristic of regulatory filings concerning changes in significant shareholdings. The presence of 'RNS Number' and the mention of the 'FCA' (Financial Conduct Authority) confirms it is a regulatory disclosure. The specific content aligns perfectly with the definition of a Major Shareholding Notification (MRQ), which covers changes in significant ownership levels crossing thresholds.
2025-05-21 English
Change of Registered Address
Regulatory Filings Classification · 1% confidence The document is very short (3319 characters) and is distributed via 'RNS Number', which is the news service of the London Stock Exchange, indicating a regulatory announcement. The content announces a 'Change of Registered Address' for N4 Pharma plc. This type of administrative update, which is not a financial report (like 10-K, IR, ER) or a specific corporate action (like DIV, CAP, DIRS), typically falls under general regulatory announcements. Since 'Regulatory Filings' (RNS) is the defined fallback for miscellaneous regulatory announcements that don't fit other specific codes, this is the most appropriate classification.
2025-05-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.